We came across a bullish thesis on Soleno Therapeutics, Inc. on X.com by seedy19tron. In this article, we will summarize the bulls’ thesis on SLNO. Soleno Therapeutics, Inc.’s share was trading at $62.74 as of October 8th. SLNO’s forward P/E was 24.15 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Soleno Therapeutics (SLNO) is a single-asset company focused on VYKAT XR, the first and only FDA-approved therapy addressing hyperphagia in Prader-Willi Syndrome (PWS) patients...
